Google_______________
Short-term Breast-feeding and Formula-feeding May Be Equally Safe for HIV Positive Mothers

By Liz Highleyman

It is known that HIV may be transmitted from mothers to babies via breast-feeding. In developed countries, HIV positive mothers are advised not to breast-feed, but in resource-limited settings, breast-feeding may be safer than formula-feeding if clean water is not readily available.

As reported in the January 16, 2007 online edition of PLoS Medicine, researchers with the ANRS 1201/1202 Ditrame Plus Study Group assessed the safety of breast-feeding in Abidjan, Cote d'Ivoire. During the period 2001-2005, HIV positive pregnant women who received antiretroviral prophylaxis around the time of delivery were presented with 2 infant feeding alternatives: formula-feeding or short-term exclusive breast-feeding through 4 months of age. Nutritional counseling and clinical management were provided for 2 years, and formula was offered for free.

The researchers collected data on the occurrence among infants of adverse health outcomes (diarrhea, acute respiratory infections, malnutrition), hospitalization, or death. The 18-month mortality rates were also compared to those observed in the earlier Ditrame trial, conducted at the same sites in 1995-1998, in which women practiced long-term breast-feeding in the absence of any specific infant feeding interventions.

Results

Out of 557 live-born children, 262 (47%) were breast-fed for a median of 4 months, whereas 295 were formula-fed.

Women who chose to formula-feed were more educated, less likely to live in shared housing, and more likely to have access to tap water in their homes compared with breast-feeding mothers.

Over the 2-year follow-up period, 37% of the formula-fed infants and 34% of the short-term breast-fed children remained free of any adverse health outcomes (adjusted HR 1.10; P = 0.43).

Formula-fed children were more likely to have diarrhea and acute respiratory infections, while breast-fed children were more likely to develop malnutrition.

The 2-year probability of hospitalization or death was the same among formula-fed (14%) and short-term breast-fed children (15%) (adjusted HR 1.19; P = 0.44).

The overall 18-month probability of survival was 96% among both short-term breast-fed and formula-fed HIV-uninfected children, which was similar to the 95% probability observed in earlier Ditrame trial.

Conclusion

"The 2-year rates of adverse health outcomes were similar among short-term breast-fed and formula-fed children," the authors concluded. "Mortality rates did not differ significantly between these two groups and, after adjustment for pediatric HIV status, were similar to those observed among long-term breast-fed children."

They added that, "Given appropriate nutritional counseling and care, access to clean water, and a supply of breast-milk substitutes, these alternatives to prolonged breast-feeding can be safe interventions to prevent mother-to-child transmission of HIV in urban African settings."

In a perspective article in the same issue, Grace John-Stewart of the University of Washington at Seattle discussed the current state of knowledge about the safety of alternative infant feeding methods.

While formula-feeding appeared as safe as short-term breast-feeding in this study -- and comparable to long-term breast-feeding in the previous Ditrame study -- she noted that these findings could not necessarily be applied to other areas in sub-Saharan Africa, or to "real world" settings that lack the close monitoring, free formula, and support offered to trial participants.

02/09/07

References

R Becquet, L Bequet, D K Ekouevi, and others (ANRS 1201/1202 Ditrame Plus Study Group). Two-Year Morbidity-Mortality and Alternatives to Prolonged Breast-Feeding among Children Born to HIV-Infected Mothers in Cote d'Ivoire. PLoS Medicine 4(1):e17. January 16, 2007.

G C John-Stewart. When Is Replacement Feeding Safe for Infants of HIV-Infected Women? [Perspective]. PLoS Medicine 4(1):e30. January 16, 2007.


 

 

Index of All HIV and AIDS
Articles by Topic ( A to Z)

FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Fortovase (saquinavir soft gel)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritronavir)
Lexiva
(Fosamprenavir)
Norvir (ritonavir)
Prezista
(darunavir)
Reyataz (atazanavir)
Viracept
(nelfinavir)

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (AZT+ 3TC)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Hivid (zalcitabine; ddC)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (Tenofovir / Emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor (delavirdine)

Sustiva (efavirenz)
Viramune (nevirapine)

Entry Inhibitors
Fuzeon (enfuvirtide; T-20)

Fixed-dose Combinations
Atripla
(efavirenz + emtricitabine + tenofovir)
Combivir
(retrovir + lamivudine)

Trizivir
(abacavir + zidovudine + lamivudine)
Truvada
(tenofovir + emtricitabine)